Med Ed Report briefs: May 2013

Share this article:
Erin Nagle
Erin Nagle

Pfizer's Medical Education Group (MEG) adopted a new name, Independent Grants for Learning & Change (IGLC), to better align with its 2012 shift toward quality and performance improvement.

Novartis and Teva lent support for a CME/CE initiative in multiple sclerosis. The personalized, teleconference-based activity—produced by Med-IQ—is designed to help NPs and PAs identify patients who are appropriate for disease-modifying therapy.

StemScientific, a division of KnowledgePoint360 Group, named Erin Nagle VP, medical & scientific services. She will lead teams of scientific directors and medical writers.

Roche said it will release to researchers the full clinical study reports on all 74 trials it sponsored for influenza drug Tamiflu. Cochrane Collaboration reviewers, which requested the data more than three years ago, said Roche has previously promised access to oseltamivir data.

The 4th annual PharmedOut conference is scheduled for June 6-7 at Georgetown University. “Medical Behavior in a Commercial World: Who is Responsible?” will feature speakers including Marcia Angell and Daniel Carlat.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?